- $24.59bn
- $21.44bn
- $8.26m
Brief: Roivant Sciences Q2 Operating Expenses USD 307.804 Million
Brief: Roivant To Report Financial Results For The Second Quarter Ended September 30, 2025, And Provide Business Update On Monday, November 10, 2025
Brief: Roivant Sciences Files For Mixed Shelf Offering - SEC Filing
Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings (updated)
Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings
U.S. STOCKS ON THE MOVE-Regeneron, Elf Beauty, Eli Lilly
U.S. STOCKS ON THE MOVE-Oruka Therapeutics, Regeneron, natgas companies
Roivant and Priovant's drug for rare skin, muscle disease shows promise in trial (updated)
Roivant Sciences rises after positive trial data for muscle-and-skin disease drug
Brief: Roivant And Priovant Announce Positive Phase 3 Valor Study Results For Brepocitinib In 52-Week Placebo-Controlled Trial In Dermatomyositis (Dm)
Roivant, Priovant Therapeutics' rare skin and muscle disease drug shows promise in trial
Roivant Sciences rises after positive trial data for its muscle-and-skin disease drug
Brief: Roivant Named On Fortune Media And Great Place To Work’s 2025 Best Workplaces In Biopharma List
Roivant Sciences Ltd reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm Roivant's Q1 revenue declines, net loss widens to $273.9 mln
Brief: Roivant Sciences Authorizes $500 Million Share Repurchase Program
Roivant Sciences Ltd reports results for the quarter ended March 31 - Earnings Summary
Brief: Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications
Brief: Roivant Sciences Says Phase 3 MG Study Meets Primary Endpoint